A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

MPS-IH (Hurler Syndrome)

Interventions

GENETIC: Experimental: OTL-203
GENETIC: Active Comparator: Allo-HSCT

Sponsor

Orchard Therapeutics